Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Vigonvita Life Sciences (旺山旺水) Pre-IPO: Window Dressing

Vigonvita Life Sciences (旺山旺水) Pre-IPO Tearsheet

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Vigonvita Life Sciences / Equity Capital Markets

<ul>
<li>Vigonvita is looking to raise at least US$100 million via a Hong Kong listing. The book runner is CITIC.</li>
<li>The company refiled its prospectus and dropped VV116, the commercialized COVID-19 anti-viral drug, from its core asset list.</li>
<li>In this note, we look at changes between filings and also further examine the prospect of LV232 and TPN171.</li>
</ul>


Vigonvita is looking to raise at least US$100 million via a Hong Kong listing. The book runner is CITIC.
The company refiled its prospectus and dropped VV116, the commercialized COVID-19 anti-viral drug, from its core asset list.
In this note, we look at changes between filings and also further examine the prospect of LV232 and TPN171.


Vigonvita Life Sciences (旺山旺水) Pre-IPO: Structural Challenges for Commercialization